Evidence map›Paper›PMID 28329397›Full record

Trial reportThe journals of gerontology. Series A, Biological sciences and medical sciences2017

Resveratrol Improves Vascular Function and Mitochondrial Number but Not Glucose Metabolism in Older Adults.

Rena M Pollack, Nir Barzilai, Valentin Anghel, Ameya S Kulkarni, Aaron Golden, Pilib O'Broin, David A Sinclair, Michael S Bonkowski, Alexander J Coleville, Danielle Powell and 6 more

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The journals of gerontology. Series A, Biological sciences and medical sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 1 pooled it
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 1 synthesis or guideline pooled it, 98 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 2 countries.

Rena M PollackAlbert Einstein College of Medicine, Bronx, New York.
Nir BarzilaiAlbert Einstein College of Medicine, Bronx, New York.
Valentin AnghelAlbert Einstein College of Medicine, Bronx, New York.
Ameya S KulkarniAlbert Einstein College of Medicine, Bronx, New York.
Aaron GoldenAlbert Einstein College of Medicine, Bronx, New York.
Pilib O'BroinNational University of Ireland Galway, Galway, Ireland.
David A SinclairHarvard Medical School, Boston, Massachusetts.
Michael S BonkowskiHarvard Medical School, Boston, Massachusetts.
Alexander J ColevilleStanford University, Palo Alto, California.
Danielle PowellAlbert Einstein College of Medicine, Bronx, New York.
Sharon KimAlbert Einstein College of Medicine, Bronx, New York.
Ruin MoaddelNational Institute on Aging, Baltimore, Maryland.
Daniel SteinAlbert Einstein College of Medicine, Bronx, New York.
Kehao ZhangAlbert Einstein College of Medicine, Bronx, New York.
Meredith HawkinsAlbert Einstein College of Medicine, Bronx, New York.
Jill P CrandallAlbert Einstein College of Medicine, Bronx, New York.
Albert Einstein College of Medicine · USHarvard University · USNational Institute on Aging · USOllscoil na Gaillimhe – University of Galway · IEStanford University · US

Funding

Disease Status Drug Metabolism and New Drug Discovery ZIAAG000297 · NIA · NATIONAL INSTITUTE ON AGING · PI EGAN, JOSEPHINE · 2009 to 2025
$38.2M
Uncovering the Human SecretomeDP1AG058605 · NIA · HARVARD MEDICAL SCHOOL · PI SINCLAIR, DAVID A. · 2017 to 2021
$5.9M
Role of Sgs1 DNA helicase in telomere maintenanceR01AG019719 · NIA · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI SINCLAIR, DAVID A. · 2001 to 2022
$5.3M
SIRT1 as a regulator of health and lifespan of mammalsR37AG028730 · NIA · HARVARD MEDICAL SCHOOL · PI SINCLAIR, DAVID A. · 2012 to 2021
$4.1M
Elucidating mechanisms of SIRT1 activationR01DK100263 · NIDDK · HARVARD MEDICAL SCHOOL · PI SINCLAIR, DAVID A. · 2016 to 2020
$2.5M
NIA NIH HHS DP1 AG058605NIA NIH HHS R01 AG019719NIA NIH HHS R37 AG028730NIDDK NIH HHS R01 DK100263
6 · The paper itself

Abstract

backgroundResveratrol, a plant-derived polyphenol, has been reported to improve glucose metabolism and vascular function and to extend life span in animal models, but studies in humans have been inconclusive.

methodsIn a randomized, double-blind crossover study, we treated older glucose-intolerant adults (n = 30) with resveratrol (2-3 g/daily) or placebo, each for 6 weeks. A standard mixed-meal test was used to assess insulin sensitivity (Matsuda index) and secretion (C-peptide deconvolution) and vascular function by reactive hyperemia peripheral arterial tonometry. Skeletal muscle samples were obtained for gene expression using RNA-Seq analysis and to assess mitochondrial morphology.

resultsThere were no changes in glucose tolerance, insulin sensitivity, weight, blood pressure, or lipid profile following resveratrol treatment. Fasting reactive hyperemia index improved with resveratrol (2.02 ± 0.2 vs 1.76 ± 0.02, p = .002). RNA-Seq analysis yielded 140 differentially expressed transcripts (corrected p-value ≤ .05), predominantly associated with mitochondrial genes and noncoding RNA. Ingenuity Pathway Analysis confirmed that mitochondrial dysfunction (p = 2.77 × 10-12) and oxidative phosphorylation (p = 1.41 × 10-11) were the most significantly perturbed pathways. Mitochondrial number, but not size, was increased.

conclusionsResveratrol treatment of older adults with impaired glucose regulation may have beneficial effects on vascular function, but not glucose metabolism or insulin sensitivity. Changes in gene expression suggest effects similar to those observed with caloric restriction, which has been shown to increase life and health span in animal models, although its significance for humans is uncertain. Future human studies should address the appropriate dose range and low bioavailability of resveratrol.

Indexed as

AgedCross-Over StudiesDouble-Blind MethodEndothelium, VascularFemaleGlucoseHumansMaleMetabolismMitochondriaResveratrolStilbenesGlucoseResveratrolStilbenesAgingGene expressionPolyphenolsPrediabetes

Identifiers

PMID28329397
PMCPMC5861959
OpenAlexW2595193138

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.